-
Thousands join Danish war vets' silent march after Trump 'insult'
-
Gaza civil defence says Israeli strikes kill 28
-
Pakistan spin out Australia in second T20I to take series
-
Melbourne champion Rybakina never doubted return to Wimbledon form
-
Luis Enrique welcomes Ligue 1 challenge from Lens
-
Long truck lines at Colombia-Ecuador border as tariffs loom
-
Ex-prince Andrew dogged again by Epstein scandal
-
Separatist attacks in Pakistan kill 21, dozens of militants dead
-
'Malfunction' cuts power in Ukraine. Here's what we know
-
Arbeloa backs five Real Madrid stars he 'always' wants playing
-
Sabalenka 'really upset' at blowing chances in Melbourne final loss
-
Britain, Japan agree to deepen defence and security cooperation
-
Rybakina keeps her cool to beat Sabalenka in tense Melbourne final
-
France tightens infant formula rules after toxin scare
-
Blanc wins final women's race before Winter Olympics
-
Elena Rybakina: Kazakhstan's Moscow-born Melbourne champion
-
Ice-cool Rybakina beats Sabalenka in tense Australian Open final
-
Pakistan attacks kill 15, dozens of militants dead: official
-
Ten security officials, 37 militants killed in SW Pakistan attacks: official
-
Epstein survivors say abusers 'remain hidden' after latest files release
-
'Full respect' for Djokovic but Nadal tips Alcaraz for Melbourne title
-
Wollaston goes back-to-back in the Cadel Evans road race
-
Women in ties return as feminism faces pushback
-
Ship ahoy! Prague's homeless find safe haven on river boat
-
Britain's Starmer ends China trip aimed at reset despite Trump warning
-
Carlos Alcaraz: rare tennis talent with shades of Federer
-
Novak Djokovic: divisive tennis great on brink of history
-
History beckons for Djokovic and Alcaraz in Australian Open final
-
Harrison, Skupski win Australian Open men's doubles title
-
Epstein offered ex-prince Andrew meeting with Russian woman: files
-
Jokic scores 31 to propel Nuggets over Clippers in injury return
-
Montreal studio rises from dark basement office to 'Stranger Things'
-
US government shuts down but quick resolution expected
-
Mertens and Zhang win Australian Open women's doubles title
-
Venezuelan interim president announces mass amnesty push
-
China factory activity loses steam in January
-
Melania Trump's atypical, divisive doc opens in theatres
-
Bad Bunny set for historic one-two punch at Grammys, Super Bowl
-
Five things to watch for on Grammys night Sunday
-
Venezuelan interim president proposes mass amnesty law
-
Rose stretches lead at Torrey Pines as Koepka makes cut
-
Online foes Trump, Petro set for White House face-to-face
-
Seattle Seahawks deny plans for post-Super Bowl sale
-
New to The Street Broadcasts Today on Bloomberg Across the U.S., MENA, and Latin America
-
AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research
-
US Senate passes deal expected to shorten shutdown
-
'Misrepresent reality': AI-altered shooting image surfaces in US Senate
-
Thousands rally in Minneapolis as immigration anger boils
-
US judge blocks death penalty for alleged health CEO killer Mangione
-
Lens win to reclaim top spot in Ligue 1 from PSG
Biden proposes huge expansion of weight loss drug access
Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald Trump's incoming health chief looked set to shoot down the idea.
Under the massive US public health insurance programs Medicare and Medicaid, drugs like Ozempic and Wegovy are, for the most part, only available for overweight people with diabetes or heart disease.
But the White House said Biden wanted to make the game-changing medications widely available as a treatment for obesity itself -- expanding coverage to nearly 7.5 million older and lower-income Americans.
"For too many Americans, these critical treatments are too expensive and therefore out of reach," a White House official said, noting that 42 percent of Americans are obese.
The Department of Health and Human Services said separately in a statement that the "transformative medications" would improve the "health and quality of life for millions of people who have obesity."
The move would benefit 3.4 million Americans with Medicare, which gives health insurance to people mainly aged over 65. It would also help four million people eligible for assistance with Medicaid, which targets lower income residents, officials said.
But the last-gasp plan appears unlikely to survive given that Trump's incoming health secretary, Robert F. Kennedy Jr., has previously spoken out against the use of anti-obesity drugs.
In October Kennedy opposed a separate bill in Congress that would have expanded access to the medications, saying the money needed to do that would be better spent on improving nutrition.
"If we spent about one fifth of that giving good food, three meals a day to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight," Kennedy said on Fox News.
- 'So stupid' -
He also accused the Danish makers of Ozempic and Wegovy, Novo Nordisk, of "counting on selling it to Americans, because we're so stupid and addicted to drugs."
Kennedy has attracted major controversy for his anti-vaccine activism and embrace of conspiracy theories -- but some of his proposals for improving American's diets have won praise from health campaigners and lawmakers.
Any plan to increase US public health insurance spending would also likely run foul of Trump's bid to slash government budgets and waste.
Trump said last week as he appointed celebrity TV doctor Mehmet Oz to head Medicare and Medicaid that Oz would "cut waste and fraud" in what he called "our Country's most expensive Government Agency."
The Republican has also named tech tycoon Elon Musk and entrepreneur Vivek Ramaswamy to head a so called "government efficiency" commission to cut costs across government.
Biden has taken a different tack during his sole term in office.
The Democrat has led a major drive to lower the exorbitant cost of US prescription medicines, and his success in forcing pharmaceutical giants to reduce the prices of some became a key plank of his reelection campaign before he dropped out in July.
In July, Biden called on Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs, saying firms must stop "ripping off the American people."
W.Morales--AT